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The kidney is often the target of immune system dysregulation in the context of primary
or systemic disease. In particular, the glomerulus represents the anatomical entity most
frequently involved, generally as the expression of inflammatory cell invasion or circulant
or in situ immune-complex deposition. Glomerulonephritis is the most common clinical
and pathological manifestation of this involvement. There are no universally accepted
classifications for glomerulonephritis. However, recent advances in our understanding of
the pathophysiological mechanisms suggest the assessment of immunological features,
biomarkers, and genetic analysis. At the same time, more accurate and targeted
therapies have been developed. Data on pediatric glomerulonephritis are scarce and
often derived from adult studies. In this review, we update the current understanding
of the etiologic events and genetic factors involved in the pathogenesis of pediatric
immunologically mediated primitive forms of glomerulonephritis, together with the clinical
spectrum and prognosis. Possible new therapeutic targets are also briefly discussed.
Keywords: review, primary glomerulonephritis, children, pathophysiology, histology, treatment, complement
cascade
INTRODUCTION
The glomerulus represents the anatomical entity of the kidney most frequently affected by
autoimmune and inflammatory diseases. Glomerulonephritis (GN) is the major clinical and
pathological expression of this involvement, which sometimes occurs in the context of systemic
diseases, such as lupus nephritis and vasculitis. The tubular-interstitial compartment of the kidney
is affected more rarely, for example in the presence of a clinical picture of interstitial nephritis.
Over recent decades, major advances have been made as regards our understanding of the
pathogenesis of some pediatric forms of GN (Table 1). n Hypocomplementemic forms represent
a wide spectrum of diseases ranging from acute (post-infectious GN) to severe forms of C3
glomerulopathies. Both the immunological and genetic mechanisms involved in their genesis have
been identified, namely the autoantibodies against the complement cascade and mutations in
genes encoding complement regulatory factors, which produce persistent activity of the alternative
complement pathway and inflammatory responses. As regards normocomplementemic GN, the
discovery of the roles of poorly O-galactosylated-IgA1 and phospholiphase A2 receptor can be
considered as a real new insight. On the other hand, the new histological classifications have
concretely contributed to a better understanding of patient prognosis and therefore tomore tailored
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TABLE 1 | Classification of primitive glomerulonephritis underlying the
pathogenetic mechanism.
Group of
diseases
Glomerulonephritis Pathogenesis
Hypocomplementemic
Glomerulonephritis
• Post-infectious GN (PIGN)
• Immunocomplex-
mediated
membrano-proliferative
GN
• C3 glomerulopathies
• Immunocomplex
deposition
• Dysregulation of
complement
alternative pathway
(acquired
or genetic)
Normocomplementemic
Glomerulonephritis
• GN due to IgA deposition
(IgA Nephropathy,
Henoch-Schönlein
Purpura associated
Nephropathy)
• Glomerulonephritis due to
in situ immune deposits
(Membranous
Nephropathy)
• ANCA Associated
Vasculitis Nephritis
• Abnormally
glycosylated
IgA deposition
• Autoantibody-
mediated
• (in situ: anti-PLA2R,
anti THSD7A)
• Autoantibody-
mediated
(systemic: ANCA)
Rapidly Progressive
Glomerulonephritis
• Immune complex related
RPGN (PIGN, IgAN,
IgAVN)
• Antibodies anti-GBM
deposition (Goodpasture
Syndrome)
• ANCA Associated
Vasculitis Nephritis
• Immunocomplex
deposition
therapies. The most recent classifications of GN, which
include histological, immunological, genetic and clinical
aspects (biomarkers) are a direct consequence of the better
understanding of the pathophysiological mechanisms underlying
these pathologies (Table 1). This is also true for GN secondary to
systemic diseases, such as Systemic Lupus Erytematosus (SLE),
for which diagnostic criteria, histological classification, clinical
and histological prognostic factors, specific biomarkers and
therapeutic approaches have changed substantially over the last
10 years.
In this review, we update the current understanding of the
etiologic events and genetic factors involved in the pathogenesis
of pediatric immunologically mediated primitive forms of GN,
together with the clinical spectrum and prognosis (Table 1).
Possible new therapeutic targets are also briefly discussed.
HYPOCOMPLEMENTEMIC
GLOMERULONEPHRITIS
All GN types characterized by complement cascade activation
are comprised in this group. Based on complement recovery
time and clinical course, these forms can be classified as either
acute: post-infectious GN (PIGN), or chronic: immune complex
FIGURE 1 | Classification of mempranoproliferative glomerulonephritis based
on IF pattern. LM: light microscopy; IF, immunofluorescence; EM, electron
microscopy.
(IC)-mediated membrano-proliferative GN (IC-MPGN) and C3
glomerulopathies (C3G).
Traditionally, the chronic forms were classified as type I, type
II and type III membrano-proliferative GN (MPGN), according
to the position of the deposits on electronmicroscopy (EM) (sub-
endothelial, intramembranous, and sub-epithelial). Following a
better understanding of the pathogenetic mechanisms involved
(Table 1), there has been a reclassification. Types I and
III MPGN, which exhibit deposits of IgG and C3 on
immunofluorescence (IF), are now considered as MPGN
caused by IC (IC-MPGN), while type II MPGN, also known
as dense deposit disease (DDD), and all the forms with
isolated/predominant C3 IF-deposits, are considered as C3G
(Figure 1). Unlike MPGN, which is characterized by classical
complement pathway (CCP) activation by IC deposition, C3G
are associated with acquired or innate dysregulation of the
alternative complement pathway (ACP).
Post-infectious Glomerulonephritis
Post-infectious GN, which is triggered by a preceding infection,
is frequently seen in children. It is most often caused by group
A ß-hemolytic streptococci, while several other bacteria and
viruses can also act as a trigger (1). In its classic form with gross
hematuria, it affects 0.5–2 children/100,000 annually, although
the pauci-symptomatic form, with microscopic hematuria, is up
to 19 times more frequent and may remain undiagnosed (2, 3).
Its incidence has drastically decreased in industrialized countries
due to antibiotic use and improved sanitation, however it is still
very common in developing countries, where the skin is the most
prevalent site of infection (1).
Clinical and Laboratory Features
Typically, the disease affects children aged between 5 and 12
years; it is very rarely seen in children younger than 2 years
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TABLE 2 | Indications for renal biopsy in case of nephritic syndrome.
1. Persistence of oligo-anuria beyond 7 days from onset
2. Persistence of renal failure beyond 10 days from onset or rapidly
progressive renal failure
3. Persistence of nephrotic syndrome beyond 2–3 weeks from onset
4. Persistence of hypocomplementemia over 12 weeks from onset
5. Recurrence of gross hematuria after more than 1 month from onset
because of the lower incidence of ß-hemolytic streptococcal
infection in this age group and a reduced ability to produce IC.
The typical clinical presentation of PIGN is a nephritic
syndrome with hematuria and proteinuria associated with signs
of water retention (edema, hypertension). An increase in urea
and creatinine values is often present, while a decrease in the
C3 fractional complement values is the rule. Neurological and
cerebral symptoms are frequently observed (10–30%) (4).
Natural History and Prognosis
In almost all cases, PIGN resolves spontaneously. Patients with
typical post-streptococcal GN following a pharyngitis infection
usually have a short illness, with rapid resolution (up to 7–10
days). Proteinuria disappears within 3 months in almost all cases,
while microscopic hematuria may persist for up to 2 years (4).
The persistence of hypocomplementemia beyond 8–12 weeks
indicates a chronic form of GN (5) and prompts the need for
further diagnostic testing, such as renal biopsy, the indications
for which are shown in Table 2.
Pathogenesis Seven to 10 days post infection, circulating
immune complexes (CICs) are formed and deposited in the
glomeruli, causing leukocyte recruitment and ACP activation.
Typically, once the infection disappears, the production of
antibodies and new CICs decreases and the deposited ICs are
cleared. As a consequence, clinical signs resolve within days to
weeks (5). The risk of developing PIGN after a streptococcal
infection has been calculated to be as high as 15% during
epidemics. The trigger antigen has not yet been identified. The
two enzymes that have been studied the most are glyceraldehyde
3-phosphate dehydrogenase, a plasmin receptor protein, and
streptococcal exotoxin B (1).
Some studies have demonstrated that there are similarities
between early C3G and PIGN. Streptococcal infection may
trigger C3G (6–11). Several reports have demonstrated the
presence of the same plasmin receptor protein in other
complement mediated glomerulopathies (12, 13). The
histological appearance of C3G may change with time.
Early renal lesions in C3G could be difficult to distinguish
from those seen in PIGN. Furthermore, the progression of
glomerular involvement in a second biopsy from patients with
persistent PIGN suggests a possible transformation into C3
glomuerulonephritis (C3GN). Finally, it is important to consider
that the presence of inherited defects in the ACP may influence
the prognosis of a patient with PIGN as it can cause delayed
recovery, with development of segmental glomerular sclerosis
and progressive chronic kidney damage (14).
Renal Histopathology (Figure 2)
Due to its specific pathogenesis, the most frequent histological
picture of PIGN on light microscopy (LM) is that of
endothelium-mesangial proliferative GN, with the presence
of immunoglobulin-G (IgG) and C3 deposits [starry sky
distribution that reflects the irregular coarse distribution along
the glomerular basement membrane (GBM)] on IF. The picture
can be complicated by epithelial cell proliferation (crescents) or
an evident pattern of extra capillary proliferative GN (crescentic
GN), which worsens the prognosis. Electronmicroscopy typically
shows subepithelial deposits (humps).
Treatment
Post infectious GN can be prevented by the early onset of
antibiotic therapy, in which case the respiratory or skin infections
may not be so clinically evident. For this reason, in the context of
epidemic infection, patients with clinical evidence of PIGN have
to be treated as though they have an active infection (15).
Treatment with steroids or cytotoxic agents might have a role
in severe or rapidly progressive diseases (Table 3). However, no
randomized trials have been conducted on the subject (1).
Immune Complex-Mediated
Membrano-Proliferative
Glomerulonephritis
This condition is also known as mesangio-capillary or
lobular GN.
Membrano-proliferative GN can be primary (idiopathic) or
secondary to different diseases, (62, 63) such as autoimmune
disorders, monoclonal gammopathies, and infections, the most
frequent being hepatitis C in adults (64). The idiopathic form is
rare. While in adults its incidence has decreased over time (65),
in children it has remained constant, likely due to the greater
number of triggering infections (66).
Clinical and Laboratory Features
In children, IC-MPGN has a variable clinical presentation. It may
include microscopic or gross hematuria, and varying degrees of
proteinuria, from absent to nephrotic range (67). Impairment of
renal function is frequent. Typically, complement activation tests
show a reduction in levels of serum C3, C4, AP50, and CH50.
Anemia and arterial hypertension can also be present at disease
onset. In secondary forms of IC-MPGN, the symptoms of the
underlying disease can overlap the clinical presentation.
Natural History and Prognosis
The course of the disease differs substantially. The important
prognostic factors, reported in both adults and children, include
deterioration of renal function, overt nephrotic syndrome (NS),
severe glomerular hematuria (>50 red blood cells per high
power field) and the presence of crescents or chronic lesions on
kidney histology. Conversely, in secondary forms, identification
of the underlying disease represents a favorable prognostic
factor as it leads to the possibility of specific treatments (16).
In pediatric patients, large population studies are lacking. The
Mexican National Institute of Pediatrics experience reported
that treatment with methylprednisolone slowed the progression
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FIGURE 2 | Post-infectious glomerulonephritis. (A) LM (PAS stain) shows endothelium-mesangial proliferative GN, with global increase of mesangial cellularity and
matrix deposition. (B) IF: Starry sky distribution of C3. (C) EM: typical subepithelial deposits (humps).
of kidney damage, while persistent anemia and macroscopic
hematuria favored kidney failure. Furthermore, the lower the
albumin and/or glomerular filtration rate (GFR) levels, the higher
the probability of developing chronic kidney disease (CKD) (63).
The Japanese focused on a prevention program: Yanagihara
et al. reported a renal survival rate of 100% at 10 years, using
high-dose steroids, with no severe adverse effects. Furthermore,
they reported that detection through school screening and the
early initiation of therapy improved prognosis (68). Finally, it
has been reported that around 40% of children and young adults
presenting with renal function impairment may progress to end-
stage renal disease within 10 years (67).
Pathogenesis
Immune complex-mediated MPGN is typically caused by a
chronic antigen stimulus with persistence of CICs (11, 16,
69, 70). The most frequent underlying disorders include
chronic infections (hepatitis B/C, streptococcal and mycoplasma
infections), autoimmune diseases (SLE, scleroderma, Sjögren
syndrome) (60, 71–79), while monoclonal gammopathies are
exceptional in children (80, 81).
Regardless of the trigger, CICs activate the CCP, leading to
the production of chemotactic factors (C5a), opsonins (C3b) and
the membrane attack complex (MAC, C5b-9), causing damage
to mesangial and endothelial cells, with consequent chemotaxis
of inflammatory cells. In response to damage, an intense cellular
proliferation occurs, with basal membrane neoformation that
traps the ICs.
Renal Histopathology (Figure 3)
Light microscopy shows a diffuse and global increase in
glomerular tuft cellularity (lobular pattern), a marked and diffuse
thickening of the glomerular capillary walls that often reveals
a duplicity of the GBM on staining (double contour or tram
track feature), and a diffuse and global reduction in the capillary
lumens. Focal crescents may also be noted in around 10% of
patients. Morphologic changes in the tubules and interstitium
may also occur. Immunofluorescence shows co-dominance of
both IgG and C3 and occasionally IgM (e.g., hepatitis C related
MPGN) or a “full house” pattern (including IgG, IgM, IgA, C1q,
C3, C4 and kappa and lambda light chains) as seen in SLE.
Treatment
Patients with IC-MPGN secondary to chronic infection or other
autoimmune/myeloproliferative disorders should be treated for
the underlying disease (Table 3) (16). There is no available
adult or pediatric randomized trial data upon which to base
treatment for patients with idiopathic IC-MPGN. It is important
to consider renal function, severity of proteinuria and the
presence of crescentic GN in the decision-making algorithm.
The Kidney Disease Improving Global Outcomes (KDIGO)
guidelines recommend, on limited evidence (17), inhibition
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TABLE 3 | Therapeutical options for glomerulonephritis.
Diseases First line treatment Other drugs
PIGN Steroids or cytotoxic agents
(1) (severe/rapidly
progressive)
Antibiotics (15)
MPGN Treatment for underlying
disease (16)(secondary
forms)
RAAS blockers (17) (mild
idiopathic form with low
proteinuria)
Oral prednisone (16, 18, 19)
(idiopathic form with
nephrotic proteinuria or
kidney function
deterioration)
pulse intravenous
methylprednisolone + oral
prednisone +
cyclophosphamide (19)
(crescentic forms)
RAAS blockers +
cyclosporine
(steroid-resistant forms)
MMF (19)
Rituximab (19)
C3G “wait-and-see” (20) (mild
disease without nephrotic
proteinuria)
Oral prednisone + MMF
(21–23) (moderate disease)
Pulse intravenous
methylprednisolone (21)
(severe disease)
Eculizumab (24, 25), plasma
exchange (26–28) fresh
plasma infusion (27, 29, 30)
(RPGN or severe disease)
calcineurin inhibitors
(31, 32)
rituximab (23, 33, 34)
(C3Nef antibodies)
C3 inhibitors, C5a
inhibitors and C5aR
antagonists (35–39)
RAAS blockers (40)
IgAN/IgAV RAAS blockers (41, 42)
(mild disease)
RAAS blockers +
corticosteroids (Pozzi’s
protocol) (moderate
disease) (42–46)
Cyclophosphamide
(42, 47, 48) (RPGN forms)
Eculizumab (48, 49)
Tonsillectomy (50, 51),
(IgAN)
Azathioprine,MMF,
cyclosporine (52)
(steroid-resistance forms)
MN “wait and see” policy (53)
(forms without kidney failure)
RAAS blocker (54–56)
(persistent proteinuria)
Cyclophosphamide/
chlorambucil/cyclosporine
(57) (steroid-resistance
forms)
Rituximab/ofatumumab
(58, 59)
AAV Pulse intravenous high dose
steroids +
cyclophosphamide (60, 61)
Rituximab (60, 61)
(refractory or relapsing
form)
Plasma exchange (renal
failure or alveolar
haemorrhage)
Low dose steroids +
azathioprine, rituximab or
MMF (maintenance phase)
of the renin-angiotensin-aldosterone system (RAAS) in mild
cases of the disease, with low proteinuria (<500 mg/day) and
normal renal function, in both adults and children. In cases
of nephrotic proteinuria with normal renal function, a course
of prednisone (1 mg/kg/day for 12–16 weeks) is suggested
(16), even if in the literature there are no confirmatory RCTs
(18). RAAS blockers and cyclosporine should be considered in
instances of steroid-resistance. Steroids may also be useful when
deterioration of renal function without crescents on biopsy is
observed, while crescentic GN should be treated with pulse
intravenousmethylprednisolone followed by oral prednisone and
cyclophosphamide. It is important to highlight the fact that
these recommendations are based on weak evidence. Recently
introduced drugs, such as mycophenolate mofetil (MMF) and
rituximab, do not appear to improve survival compared to
cyclophosphamide (19).
In our experience, long-term high dose alternate-
day oral prednisone (1 mg/kg/alternate days) after
steroid pulse induction therapy (methylprednisolone 15
mg/kg/dose for 3 days) is a useful therapy. It is rarely
necessary to add an immunosuppressive agent (e.g.,
MMF) as a first-line drug, though this may be due to
the lack of experience in the literature regarding the use
of this drug.
C3 Glomerulopathies
C3G are the pathological entities characterized by isolated C3
deposits, with minimal or no immunoglobulin deposition. The
first international C3G meeting took place in Cambridge (UK)
in 2012. The following year, the first consensus report on the
definition, management, and treatment of C3G was published.
The best-known forms are DDD and C3GN, based on EM
findings and disease severity (61).
As this entity has been described relatively recently, its exact
prevalence is difficult to estimate. The incidence of C3GN has
been reported as 1–2 cases per million inhabitants (82), with a
greater prevalence in the younger age group and a slight male
preponderance (83, 84).
Clinical and Laboratory Features
The clinical spectrum is heterogeneous, ranging from mild
disease with asymptomatic microscopic hematuria with or
without proteinuria, to severe disease with a nephritic/nephrotic
picture. Hematuria has to be considered pathognomonic
of the disease. The presentation at onset is similar to DDD
and C3GN (20), with minor differences reported in some
series (84–86). Evidence of a preceding infection is present
in 28–54% of patients, (11, 84, 87) many of whom were
initially incorrectly labeled as PIGN. However, PIGN has
more severe renal impairment and lower serum C3 levels
at disease onset (88). In C3G, extra-renal manifestations
such as acquired partial lipodystrophy, ocular deposits
of C3 (Drusen) and thrombotic microangiopathy may
occur (83, 85, 89).
Natural History and Prognosis
Most C3G patients have a chronic course, with persistent
ACP dysfunction (low C3 levels in up to 75% of cases) with
normal or slightly reduced C4 concentrations (11). Published
data on the clinical course are, to date, few and conflicting.
This is because the real prognosis varies according to the
characteristics of the reported cases and the length of the follow
up considered. However, clinical expression is so variable that
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FIGURE 3 | Immunocomplex-mediated membrano-proliferative GN. (A) LM (PAS stain): diffuse and global increase of glomerular tuft cellularity (lobular pattern) with
thickening of the glomerular capillary walls (membranoproliferative pattern). (B) Arrows indicate GBM splitting due to mesangial interposition (white arrow where) and
presence of mesangial and sub-endothelial deposits (black arrow). (C) IF shows IgG and C3 co-dominant positivity.
it can independently affect prognosis (11, 83, 84). Nonetheless,
the following risk factors have been identified: creatinine values
>1.5 mg/dl at onset, renal histology showing crescents, severe
arteriolar sclerosis, or DDD. The recurrence rate of the disease
following transplantation was 50–55% for DDD and 43–67%
for C3GN, (83, 84, 90, 91) with secondary graft loss in 50%
and graft survival rates of 94–69–28% at 1, 5, and 10-years,
respectively (91).
Pathogenesis
Both DDD and C3GN are driven by the dysregulation (acquired
or congenital) of the ACP, however the specific mechanisms are
unknown (Figure 4). It has been suggested that dysregulation of
earlier components at C3 levels is implicated in DDD, whereas
the late/terminal components are implicated in C3GN (84, 92).
This could explain the aggressive course seen in DDD (10).
Regardless of the mechanisms, the outcome is hyperactivity of
C3 convertase which causes a persistent C3 cleavage into C3a and
C3b, maintaining ACP activity. The excessive formation of C5b-9
or MAC determines the cytotoxic effects responsible for cellular
lesions. Acquired C3G is considered an autoimmune disease,
given the presence of autoantibodies that block the function
of complement cascade proteins. In 1965, Spitzer et al. were
the first to describe the autoantibody directed against the C3
convertase of the ACP, C3 Nephritic Factor (C3NeF) (93), which
was subsequently reported in up to 86% of patients with DDD
and 46% of those with C3GN (83).
However, the exact role of C3NeF is incompletely understood:
levels may vary regardless of disease activity, and be transiently
present in PIGN (87, 94). In recent decades, some authors have
described antibodies against Complement Factor H (CFH), the
main regulatory protein of the ACP and, more rarely, against
Factor B (CFB) and C3b (95). More recent data suggest a role for
C4NeF, an autoantibody recognizing C4b2a, the C3 convertase
for the CCP, in driving complement dysregulation in patients
without other risk factors (96). The regulatory proteins of the
ACP are genetically mutated in the congenital forms. In such
cases, C3G may develop in the presence of a trigger. Mutations
in the CFH gene, first described in 2006 in two brothers (29),
are the most frequent. Other mutations in genes encoding
C3, complement Factor I (CFI), CFB, factors related to CFH,
CFHR1–5 and CD46 (MCP) have been associated with C3G, as
already described in atypical hemolytic-uremic syndrome (97,
98). In particular, mutations in CFHR5 define an autosomal
dominant disease termed CFHR5 Nephropathy, endemic among
people of Cypriot ancestry and characterized by synpharingitic
hematuria with a poor prognosis in male patients (99, 100).
Mutations of complement factors have been described in up to
17% of patients with C3GN and 20% of patients with DDD (83).
Currently, no genotype-phenotype correlation has been
recognized (20). It is strongly recommended that genetic testing
be performed and interpreted by a center with expertise in
atypical hemolytic-uremic syndrome and C3G (21).
Renal Histopathology
C3G show various histological patterns of glomerular injury
(Figures 5, 6), including mesangial proliferative, diffuse
endocapillary proliferative and crescentic glomerulonephritis
(10, 101–103). The IF aspect represents the key diagnostic feature
showing the presence of C3 dominant staining (C3 intensity
Frontiers in Pediatrics | www.frontiersin.org 6 May 2020 | Volume 8 | Article 205
Mastrangelo et al. Immunological Mediated Glomerulopathies in Children
FIGURE 4 | Activation pathways of the complement system in normal subjects. It is possible to note the complement regulation factors, such as CFH and CFI, and
their point of action along the cascade phases (e.g., the C3 conversion for the CFH and CFI factors).
FIGURE 5 | C3 Glomerulonephritis. (A) LM (PAS stain) shows lobular pattern with evidence of diffuse endothelium-mesangial proliferative GN. (B) EM demonstrates
the splitting of GMB due to mesangial interposition (arrows). The lower image shows the presence of low intensity electron-dense sub-epithelial deposits (arrow). (C) IF
shows the presence of C3 dominant staining.
at least twice that of any other immune reactant). In DDD,
EM typically reveals the presence of electron-dense deposits
along the entire course of the GBM (ribbon-like appearance)
and occasionally along the tubular basement membrane and
Bowman’s capsule. Otherwise, C3GN EM is characterized
by less intense and less well-defined electron-dense deposits
(mesangial, sub-endothelial, intramembranous or sub-epithelial)
(61). Humps, previously considered pathognomonic of PIGN,
have recently been described in IC-MPGN and C3G on EM
(104). It is interesting to note that PIGN can exhibit isolated
C3 deposition on IF, particularly during the post-acute phase
(14), when C3 amplification may be persistent and deposition
of IgG decreases to undetectable levels (105). All these features
indicate that PIGN, C3G, and MPGN could represent a
spectrum of GN, with either primary or secondary complement
activation, often triggered by infections (106). In this regard,
Frontiers in Pediatrics | www.frontiersin.org 7 May 2020 | Volume 8 | Article 205
Mastrangelo et al. Immunological Mediated Glomerulopathies in Children
FIGURE 6 | Dense Deposit Disease. (A) LM (PAS stain): global thickening of GBM associated with lobular pattern. (B) IF shows isolated C3 positivity
(mesangial/capillary wall distribution). (C) EM, typical electron-dense deposits along the entire course of the glomerular basement membrane (ribbon-like appearance).
glomerular staining of C4d (and rarely C1q), a by-product of
CCP activity, is considered a useful tool in the identification
of an IC-mediated mechanism, as observed in PIGN and
IC-MPGN (106, 107).
Treatment
No adequate clinical trials evaluating the treatment of C3G
are available. Recommendations and therapeutic algorithms are
based on expert opinion and scanty published data (Table 3).
Steroid monotherapy proved ineffective in adult patients with
DDD in the only randomized clinical trial in the literature (18).
The use of MMF was reported to be useful in C3GN (22),
while the use of calcineurin inhibitors (31, 32) or rituximab
(33, 34) were inefficacious. The identification of the role
played by ACP activation has opened up new perspectives
for the treatment of C3G. It is important to underline that
the utility of biomarkers such as C5b-9 plasma levels in
predicting treatment response and customizing therapy remains
unclear (25). Eculizumab, a recombinant humanizedmonoclonal
antibody directed against the C5 fraction of complement, was
tested in DDD and C3GN pediatric patients (24) and in adult
patients with crescentic/rapidly progressive GN (RPGN) (108)
with good results. In any case, the optimal duration of eculizumab
therapy in responders, and useful parameters in patient selection,
remain unclear, though a limited treatment duration may be
sufficient. The effective removal of C3NeF with plasma exchange
proved ineffective (26), while partial or complete remission was
reported in 17 out of 21 (81%) cases (27, 28). Case reports
involving fresh plasma infusion claimed prevention of disease
progression in 3 patients (2 DDD and 1 IC-MPGN) (27, 29, 30).
Recently, more targeted agents have been proposed: C3 inhibitors
(compstatin and staphylococcal C inhibitor), C5a inhibitors and
C5aR antagonists (PMX-58 and AcePepA, soluble CD59, and
clusterin) (35–39).
In conclusion, from a practical point of view, two main
therapeutic lines have been suggested:
- KDIGO recommends the use of steroids andMMF for patients
with moderate disease and intravenous methylprednisolone
for severe disease, while insufficient data are available to
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recommend the use of eculizumab for rapidly progressive GN
with isolated C3 deposits (21).
- Riedlet et al. (20) suggest a “wait-and-see” approach for
patients with normal renal function without nephrotic range
proteinuria. In the other cases, prompt treatment with fresh
frozen plasma, plasma exchange or eculizumab, to restore
complement function, is suggested (27, 30) adding steroids
and MMF or rituximab in patients with positive C3Nef
antibodies (23).
The use of RAAS blockers (single or double blockade) has been
strongly suggested for reducing proteinuria (40, 83), despite the
persistence of low C3 levels, because an increase in renal survival
has been observed.
In our experience, an intensive course of immunosuppression
is administered to patients with a urinary protein to creatinine
ratio (uPr/uCr) >0.5–1 mg/mg in order to reduce renal
inflammation and systemic autoimmune activation, which affects
the complementary cascade. We thus prescribe 1 to 3 cycles of
three boluses of methylprednisolone (15 mg/kg/dose), followed
by oral prednisone (1 mg/kg every other day), eventually adding
an immunosuppressive agent (MMF). We usually prescribe
RAAS blockers after 3 months to properly assess the effectiveness
of the induction therapy.
NORMOCOMPLEMENTEMIC
GLOMERULONEPHRITIS
Glomerulonephritis Due to Abnormally
Glycosylated IgA Deposition
Immunoglobulin A nephropathy (IgAN) and Henoch-Schönlein
purpura nephritis (HSPN), also known as immunoglobulin
vasculitis nephritis or anaphylactoid purpura nephropathy, are
two pediatric glomerulopathies resulting from the glomerular
deposition of an abnormally glycosylated IgA1, with mesangial
proliferation (42).
IgA Nephropathy
Immunoglobulin A nephropathy or Berger’s disease, first
described in 1968 by Berger and Hinglais, is the most common
type of primary GN throughout the world in adolescents and
young adults, with a male predominance (109, 110). It has a
higher incidence in Asia and Australia (24–30% of all GN)
and Europe (18%) than in the United States (2–10%): these
differences are in part related to a different “biopsy policy” (110),
as regards microscopic hematuria.
Clinical and Laboratory Features
Clinical manifestations vary from asymptomatic microscopic
hematuria to RPGN. Typically, the recurrence of gross
haematuria coinciding with a febrile infection is the presenting
symptom. Urinary abnormalities can be persistent between acute
events or may represent the only clinical finding. A renal biopsy
is necessary to determine the diagnosis (111).
Natural History and Prognosis
Although initially considered a benign disease, 10% of children
and up to 40% of adults with IgAN progress to end stage
kidney disease within 20 years (42, 50), with a risk of recurrence
after kidney transplant of up to 50% (112). Several clinical and
histological risk factors for progressive kidney damage have
been identified, both in adults and children, hypertension at
renal biopsy and proteinuria being the most relevant (53, 113–
117). In the Validation of the Oxford Classification of IgAN
(VALIGA) study (>1,000 patients from 13 European countries),
the threshold of persistent proteinuria as a risk factor for a 50%
reduction in GFR or need for dialysis was >0.5 g/day (118).
Conversely, proteinuria at onset was not associated with bad
prognosis, probably because it represents the consequence of
the acute inflammation, reversible with steroid therapy. Gross
hematuria, per se, is not prognostic (119), but persistence of
severe microscopic hematuria has recently been considered
a risk factor (120). Glomerular filtration rate at biopsy is a
predictor of the need for dialysis in adults (118, 121–124).
Adverse histology includes the presence of extensive (>25%)
fibrosis, crescents and mesangial proliferation. The predictive
value of mesangial hypercellularity and crescents is attenuated
by immunosuppression, indicating that proliferative lesions are
steroid-responsive, particularly in children (112, 125). Finally, the
presence of C4d on renal biopsy has been recently proposed as a
new negative prognostic biomarker (126, 127).
Pathogenesis
IgAN has recently been redefined as an immune complex-
mediated disease with a multi-hit pathogenesis, in which
genetic and epigenetic factors play a role in association with
the intestinal microbiota (gut-kidney axis) and the mucosal-
associated lymphoid tissue (50, 109–111).
Genetic susceptibility plays a major role in this pathway
and it has to be considered as “the first hit.” Mutations in
genes encoding glycoprotein-N-acetylgalactosamine-3-β-
galactosyltransferase (C1GalT1), an enzyme involved in the
post-translational galactosylation of circulating lymphocytes
(49, 109), B-cell Activating Factor (BAFF) and A PRoliferation-
Inducing Ligand (APRIL) play a major role (109). On the other
hand, mutations in CFHR1–3 genes appear to have a protective
role, because the absence of these complement regulatory
proteins (CFHR1–3) increases CFH activity with a more effective
inhibition of ACP and a reduced production of C3a (111).
Following antigen exposure (environmental or dietary
antigens, mucosal infections), the innate immune system is
excessively activated by the Toll-like receptors, B-cell activating
factor and proliferation-inducing ligand signaling (49). As
a result of mis-homing of a proportion of mucosal B cells
to systemic sites, poorly O-galactosylated-IgA1 (Gd-IgA1)
is secreted into the circulation by gut lymphocytes with
autoantibody production against the Gd-IgA1 hinge region
and nephritogenic immune complex formation (49, 50, 109–
111). The glomerular deposition of these ICs is favored by the
dysregulation of CD71, a receptor on mesangial cells stimulated
by soluble CD89, which is involved in IgA complex amplification,
the activation of mesangial cells and pro-inflammatory cytokine
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(IL-6, IL-8, IL-1β, TGF-β) release. This cascade of events alters
GBM permeability with the consequent damage of podocytes
and proximal tubule epithelial cells. Finally, the activation of
the ACP and the lectin complement pathway (LCP) completes
the process of renal damage, contributing to glomerulosclerosis
and tubulointerstitial fibrosis (49, 50), and playing a crucial role
in leukocyte infiltration of the kidney and an essential role in
disease progression (109).
Renal Histopathology
Immunofluorescence findings of mesangial IgA deposits,
commonly associated with C3 deposition, is the key diagnostic
feature (Figure 7). On LM, findings vary from minimal
mesangial expansion to diffuse proliferative lesions with
crescents and/or widespread sclerosis. More often, there is an
increase in the mesangial area, due to the expansion of mesangial
cells, matrix, and deposits. Endocapillary proliferation may be
present (focal segmental or diffuse) and is typically associated
with the extension of deposits into the subendothelial areas
of the peripheral loops. In severe cases, segmental necrosis
and crescents may be seen. Chronic cases are characterized
by segmental sclerosis with proportional tubular atrophy and
interstitial fibrosis, the presence of which is confirmed by EM.
The recently updated 2016 Oxford classification (MEST-
C) (125) considers each pathological feature separately. The
VALIGA study demonstrated the presence of mesangial
hypercellularity (M), endocapillary hypercellularity (E),
segmental glomerulosclerosis (S), tubular atrophy/interstitial
fibrosis (T), and glomerular crescent formation (C) (49, 112) as
independent predictors for developing progressive renal disease
in adults (112, 118, 125).. In a cohort of 174 patients under 18
years of age, the presence of mesangial proliferation (M1) was
the sole predictor of poor outcome with a survival rate of 46% at
15 years vs. 100% with no proliferation (M0) (128).
Treatment
In the past, IgAN was considered by many nephrologists to be
a benign condition not requiring treatment. For this reason,
no evidence-based treatment guideline for pediatric IgAN is
available. Althoughmany therapeutic trials have been conducted,
in 2006, Appel concluded that there was no consensus on the best
treatment (129, 130).
Over the last 10–15 years, several randomized controlled
studies in adult patients have been published, contributing to the
2012 KDIGO guidelines (Table 3).
IgAN with minimal glomerular abnormalities can
spontaneously remit. When proteinuria is < 0.5 g/24h, with
normal eGFR, RAAS blockers are the recommended therapy
(41). The most effective treatment for patients with normal,
or almost normal, renal function and moderate proteinuria
should be a combination of RAAS blockers and corticosteroids
(43–46). It is important to underline that the KDIGO guidelines
discourage corticosteroid use in patients with an eGFR <30 ml/
min (131), given the presence of chronic lesions on histology.
Cyclophosphamide is reserved for rapidly progressive IgAN,
reducing the frequency of end-stage renal failure (47). In
randomized prospective studies, MMF was ineffective in the
short-term, but provided renoprotection in the long-term in
adults (52).
In pediatric patients with IgAN, we prescribe an observational
follow up (every 6 months) for those with microscopic hematuria
or recurrence of gross hematuria without persistent proteinuria.
Children with mild proteinuria (uPr/uCr <0.5–1 mg/mg) are
treated with RAAS blockers and/or ARBs, with dosage titration.
In patients with uPr/uCr >0.5–1 mg/mg, 3 daily pulses of
methylprednisolone at months 1, 3, 5, plus oral prednisone 0.5
mg/kg every other day for 6 months, followed by tapering for
6 months with the addition of RAAS blockers is recommended.
We recommend cyclophosphamide in patients with the rapidly
progressive form.
Rituximab is not effective in IgAN patients, despite systemic
CD20 B cell depletion. Temporary benefit in stabilizing renal
function or proteinuria was observed in two patients with rapidly
progressive IgAN treated with Eculizumab (49). Tonsillectomy,
polyunsaturated fatty acids and statins have been suggested
but are not widely accepted forms of treatment (50, 51). New
immunomodulatory strategies have been attempted with good
preliminary results (49).
Henoch–Schönlein Purpura Nephritis
(HSPN)
Henoch–Schönlein purpura nephritis (HSPN) is a GN secondary
to a systemic disease and is characterized by leukocyte infiltration
of the small blood vessel walls, with added IgA1 immune
complex deposition (42). Henoch–Schönlein purpura is the most
common pediatric vasculitis in Western countries (estimated
incidence rate of 30/100,000 children per year) that usually
affects children from 3 to 10 years of age, during the autumn
and winter months. A higher incidence has been reported in
white, Asian and Hispanic populations than in black populations
(132). Male gender, age >10 years, severe gastrointestinal
symptoms (abdominal pain, gastrointestinal bleeding, severe
bowel angina), arthritis/arthralgia, persistent purpura or relapse,
white blood cells >15 x 109/L, platelets >500 x 109/L, elevated
antistreptolysin O and low C3 concentrations are described as
risk factors associated with renal involvement in HSP (133).
Clinical and Laboratory Features
Henoch–Schönlein purpura is a self-resolving necrotizing
vasculitis, triggered by upper respiratory tract infections. It is
clinically characterized by a non-thrombocytopenic palpable
purpuric rash on the ankles and lower legs associated with
articular (arthralgia/arthritis, edema), gastrointestinal (bloody
stools, abdominal pain) and renal disease (gross or microscopic
hematuria) (42). The European League Against Rheumatism
(EULAR), the Pediatric Rheumatology International Trials
Organization (PRINTO) and the Pediatric Rheumatology
European Society (PRES) (EULAR/PRINTO/PRES) defined the
diagnostic criteria for HSP diagnosis (Table 4) (134).
Renal manifestations occur in up to 80% of pediatric patients,
typically within 6 months of disease onset, ranging from urinary
abnormalities (microscopic or gross hematuria with or without
proteinuria, in 50% of cases) to nephritic/nephrotic syndrome
(20% of cases), usually associated with acute renal failure and
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FIGURE 7 | IgA Nephropathy. (A) LM (PAS stain): Two glomeruli show diffuse and global mesangial proliferative lesions, with endocapillary proliferation. (B) IF, global
and diffuse mesangial IgA deposits, associated with C3 and IgG deposition. (C) EM, presence of paramesangial immune deposits (arrows).
arterial hypertension (135). For all these reasons, urine testing
to monitor kidney involvement is mandatory (48). We suggest
performing a urinary dipstick weekly for 1 month, every 2 weeks
for 2 months and monthly for 3–6 months. A renal biopsy is
suggested in patients with persistent proteinuria (>1 mg/mg for
4 weeks) or impaired GFR at onset (110, 135).
Natural History and Prognosis
Renal prognosis is good in most cases as the condition eventually
resolves. Children with persistent renal inflammation and
crescentic glomerulonephritis (>50%) may progress to ESRD in
up to 20% of cases (48). Glomerular crescents, tubulointerstitial
or chronic lesions are the prognostic factors most correlated with
poor outcome (135).
Renal Histopathology
The pathologic lesions are similar to those seen in other IC–
mediated diseases, in particular lupus nephritis. The findings
range from pure mesangial proliferative GN to focal segmental
necrotizing GN. Sometimes a pattern of MPGN can be present,
often associated with crescents. The glomerular inflammatory
lesions have been conventionally classified by the International
Study of Kidney Disease in Children (ISKDC) (Table 5) (136).
The Oxford classification has also been proposed, but has
not yet been validated (135). Immunofluoresence demonstrates
mesangial to peripheral capillary deposition of IgA, which is a
clue to diagnosis.
Pathogenesis
Similarly to IgAN, it has been hypothesized that HSPN has
a multi-hit pathogenesis, triggered by an abnormal immune
response to a number of antigenic stimuli (bacteria such
as H. pylori, S. pneumoniae, H. influenza or viral agents)
in genetically susceptible subjects (137). Galactose deficient-
IgA1 is the main component of large immune deposits,
together with IgG autoantibodies and CD89, which are
deposited in the mesangium leading to inflammation of
the glomerulus, as previously described in IgAN. Genetic
association studies identified HLA-DRB1∗07 as a protective locus
and HLA-DRB1∗01 and HLA-DRB1∗11 as predisposing loci
(132). Other gene polymorphisms involved in cytokine and
chemokine production, the renin-angiotensin system, aberrant
IgA1 glycosylation, neoangiogenesis, nitrite oxide production,
complement activation, and endothelium activity regulation have
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TABLE 4 | EULAR/PRINTO/PRES diagnostic criteria for Henoch-Schönlein
Purpura diagnosis.
Criterion Frequency
(%)
Palpable purpura plus
one of the following
Symmetric purpura, mainly
over extremities following
gravity
Exclude thrombocytopenia
100
Abdominal pain Colic-like, postprandial
Nausea, gastrointestinal
bleeding
Intussusception,
infarction, perforation
50
Histopathology Immune complex vasculitis
Proliferative glomerulonephritis
(IgA deposition)
-
Kidney involvement Proteinuria >0.3 g/24 h or
Albumin/creatinine ratio >30
mmol/mg
Micro-hematuria
Arterial hypertension
Nephritic or
nephrotic syndrome
20–40
Joint involvement Arthritis, mostly ankles
and/or knees
70
TABLE 5 | Classification of renal lesions in course of Henoch-Schönlein Purpura
by the International Study of Kidney Disease in Children (ISKDC).
ISKDC grade Description
Grade I Minimal alterations
Grade II Mesangial proliferation
Grade III Proliferation or sclerosis with < 50% crescents ((a) focal
or (b) diffuse)
Grade IV Mesangial proliferation or sclerosis with 50–75%,
crescents ((a) focal or (b) diffuse)
Grade V Mesangial proliferation or sclerosis with > 75%
crescents ((a) focal or (b) diffuse)
Grade VI Membranoproliferative like glomerulonephritis
all been implicated in HSPN susceptibility and severity (137,
138).
Treatment
Since 2012, the KDIGO guidelines have proposed the same
treatment for IgAN and HSPN, based on disease severity with
the optimal proteinuria target <0.5 g/24 h/1.73m (2). However,
HSPN has more acute histological features, while IgAN has a
more chronic imprinting, Therefore, the use of the same therapy
scheme is not universally accepted (42). It must be remembered
that KDIGO recommendations are based on patients with IgAN.
For this reason, in 2019, the European Consensus of
pediatric rheumatologists produced new recommendations
for HSP (Table 3). They recommend corticosteroids
and immunosuppressive agents as first-line therapy for
mild/moderate and severe HSPN in the acute phase in order
to prevent CKD, in association with RAAS blockers when
proteinuria is present. When GFR is normal and uPr/uCr
<2,5mg/mg, oral prednisolone is indicated, plus steroid sparing
agents (azathioprine, MMF, cyclosporine) when there is a lack
of response to oral steroids. Intravenous cyclophosphamide
with corticosteroids is recommended in children with severe
HSPN (>50% crescents on biopsy and impaired GFR or severe
persistent proteinuria) followed by azathioprine and MMF. The
use of rituximab is not recommended (48).
We employ 3-daily pulses of methylprednisolone (15
mg/kg/dose, months 1,3,5) followed by oral prednisone
(0.5–1 mg/kg every other day) for 6 months, and
then tapering, as the first-line treatment. We consider
immunosuppressive drugs (cyclophosphamide in the induction
phase and MMF/azathioprine in the maintenance phase) for
severe/crescentic or steroid-resistant cases. We use RAAS
blockers after 3 months, in order to evaluate the efficacy of the
induction therapy.
Glomerulonephritis Due to in situ Immune
Deposits: Membranous Nephropathy
Membranous nephropathy (MN) is a non-inflammatory organ-
specific autoimmune disease affecting the glomerulus, resulting
in the formation of immune deposits on the outer aspects of the
GBM. Membranous nephropathy can occur in all age groups,
from infancy to old age. In the adult population, it is the
commonest cause of NS, while the percentage drops to 3% in
children under 13 years of age and rises to 18% in adolescents
(139). Data from the ISKDC demonstrates an incidence of 1.5%
in children with NS (140).
In the majority of children, it is secondary to infections,
particularly hepatitis B in endemic areas, and systemic
diseases, mainly SLE. In the remaining cases, it is defined
as “idiopathic.” Malignancy associated MN is very rare in the
pediatric population.
Clinical and Laboratory Features
The most frequent (40–75%) clinical pattern at onset is NS (139).
Proteinuria is present in all cases of MN, even if non-nephrotic.
Kidney function and blood pressure are generally normal. The
presence of hematuria (70% microscopic, 30% gross) is more
common in children than in adults (139, 141).
Natural History and Prognosis
Evolution is extremely variable: spontaneous remissions occur
in 35–50% during the first 2 years (142). Progression to ESRD,
although slow and less frequent than in the adult population, is
seen in 20% of children with persistent NS. In 2008, the North
American National Report on Pediatric Kidney Disease indicated
that MN is responsible for 0.4% of pediatric ESRD and 0.5% of
pediatric causes of CKD (143). No prognostic factors have been
identified in pediatric patients. Adult studies showed that anti-
PLA2R titers correlate with disease activity and patient outcomes:
(58, 144, 145) a low titer predicts spontaneous remission, while
a high titer (>275 IU/ml) is associated with NS, a high risk
of relapse and progressive loss of renal function. Preliminary
data suggest that the same holds true for anti-THSD7A levels
(146). Likewise, the nature of antibodies influences disease
severity: those targeting the CTLD1 and CTLD7 domains of
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PLA2R1 are detectable in older patients with more severe
proteinuria, rare spontaneous remission and higher risk of
progression to ESRD (147). Other negative prognostic factors
that have been reported at disease onset include low molecular
weight urinary proteins, elevated serum creatinine, severity of
proteinuria and presence of tubular-interstitial fibrosis at renal
biopsy (148).
Pathogenesis
Our understanding of the pathogenetic mechanisms goes back
to the experimental model of Heymann nephritis and to
investigations that demonstrated glomerular antigens in the
extra-membranous area. In humans, the first target antigen to be
discovered was neutral endopeptidase (NEP), a protein expressed
on podocytes. During pregnancy, women with NEP deficiency
develop anti-NEP antibodies that cross the placenta and bind to
the NEP expressed on fetal podocytes. After birth, a congenital
form of NS develops (149–153). Recently, the phospholipase 2
receptor (PLA2R) glycoprotein expressed by podocytes has been
identified as the most frequent target of autoantibodies (anti-
PLA2R) in up to 70–80% of adult cases of MN, but in only
40–50% of children, thus leaving the door open for other causal
antigens. Another human podocyte antigen, the thrombospondin
type 1 domain-containing 7A protein (THSD7A), has been
more recently identified in 5–10% of patients (146) and is
associated with malignancies (154). In children <5 years of age,
the presence of circulating anti-bovine serum albumin antibodies
(anti-BSA) and the finding of bovine serum albumin (BSA) and
IgG anti-BSA in subepithelial deposits implies the pathogenetic
role of an exogenous glomerular antigen (155). It has been
postulated that the metabolic action of the intestinal microbiota
leads to cationic modifications of the BSA, which can then
cross the GBM and accumulate on its subepithelial anionic
side (156).
Renal Histopathology
The typical histopathological lesion is thickening of the GBM,
related to the presence of immune deposits (Figure 8). During
the early phases, a more rigid-appearing capillary wall may be
present, with no surrounding GBM reaction (spikes). Initial
immunoglobulin deposition appears like “holes” in the silver
staining, as they do not stain with silver (Stage 1). As deposits
persist, the GBM matrix reaction produces small spike-like
protrusions (Stage 2) visualized by silver staining, followed
by the matrix encircling the deposits resulting in a lace-
like splitting of the GBM (Stage 3). Finally, the deposits are
reabsorbed (Stage 4). Additional lesions include segmental
sclerosis, interstitial fibrosis, and tubular atrophy, generally
associated with a worse prognosis. Crescents are very rare and
should raise the suspicion of SLE or anti-GBM nephritis. Also,
the presence of mesangial deposits suggests a secondary form
(Class V Lupus Nephritis). Diffuse and granular subepithelial
deposits of IgG and, less frequently, C3 along the capillary wall
are present on IF. Mesangial deposits are typically present in
secondary forms. On EM, deposits corresponding to the stage
of the disease are visualized, with a variable surrounding GBM
reaction (139).
Treatment
Spontaneous remission occurs in up to a third of patients, even if
the initial presentation includes massive proteinuria (157). This
finding supports the 6-month “wait and see” policy, unless a
rapid loss of GFR is present or life-threatening NS complications
occur (53). Thereafter, patients with persistent proteinuria
should be treated with supportive anti-proteinuric therapy
(RAAS blockers), although less effective than in other chronic
nephropathies (55, 56). Immunosuppressive drugs are utilized
in patients with a severe disease or steroid-resistant nephrotic
proteinuria (Table 3). Cyclophosphamide and chlorambucil, and,
less frequently, cyclosporine, for at least 6 months all produce
positive results albeit with greater side effects (57). Recently, the
efficacy of rituximab and other anti-CD20monoclonal antibodies
has been reported in adults and children, with fewer side effects
(58, 59, 158). However, rituximab therapy may fail in 25–30%
of patients with NS because of an escape phenomenon vs. anti-
CD20 treatment (57).
In our patients older than 5 years of age with anti-PLA2R
autoantibodies, we start treatment with rituximab (2 doses of
375 mg/sm administered 14 days apart) and monitor levels of
antibodies and CD20-cells. In children younger than 5 years
and in older children without autoantibodies we prefer steroids
(prednisone 2 mg/kg for 4 weeks than slowly tapered in 3–6
months) and cyclosporin (3–5 mg/kilogram of body weight for
12 months).
Anti-neutrophil Cytoplasmic
Antibody-Associated Vasculitis
Anti-neutrophil cytoplasmic antibody (ANCA)-associated
vasculitis (AAV) is characterized by the destruction of small
and medium-sized arterial vessels with few or no immune
deposits, in the presence of circulating autoantibodies
toward the cytoplasmic region of the neutrophil (ANCA)
predominantly against proteinase-3 (PR3) and myeloperoxidase
(MPO). Very rare cases are negative for ANCA, but they are
considered in the same spectrum of the disease. Anti-neutrophil
cytoplasmic antibody-associated vasculitis includes 3 different
entities: granulomatosis with polyangiitis (GPA) or Wegener’s
granulomatosis; eosinophilic granulomatosis with polyangiitis
(EGPA) or Churg-Strauss syndrome; microscopic polyangiitis
(MPA). The emerging importance of ANCA serology in
predicting outcome and risk of relapse has led to some new
terminology. The new nomenclature considers the autoantigen
involved (MPO/PR3) adding the relevant clinical manifestations,
preferably using the terms GPA/MPA/EGPA, where present (e.g.,
PR3-AAV with clinical manifestations of GPA) (159).
The overall incidence is of 0.5–2 per million children per
year in Europe, making AAV a rare disease (160, 161). A female
predominance and onset in early adolescence (11–14 years) have
been described (162).
Clinical and Laboratory Features
In 2008, the EULAR/PRINTO/PReS societies validated the
classification of GPA (Table 6) (25, 160), with common clinical
manifestations, even if single organ involvement has been
reported. No specific criteria for childhood-onset MPA (Table 7)
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FIGURE 8 | Membranous Nephropathy. (A) LM shows (PAS stain) regular and diffuse thickening of GBM without endothelium-mesangial proliferation and (silver stain)
the GBM matrix reaction due to the presence of deposits (spikes). (B) EM shows sub-epithelial deposits with spikes of GBM that begin to encircle the deposits (Stage
1). (C) IF: diffuse and granular subepithelial deposits of IgG along the capillary wall (garland pattern).
TABLE 6 | According to EULAR/PRINTO/PReS criteria, the definition of GPA
requires three out of six criteria (Sensitivity 93%, Specificity 99%).
Criterion Pattern
Renal involvement Proteinuria, hematuria, or red blood cell
casts
Positive histopathology Granulomatous inflammation within the
wall of an artery or perivascular or
extravascular area
Upper airway
involvement
Nasal discharge or septum perforation,
sinus inflammation
Laryngotracheobronchial
involvement
Subglottic tracheal or bronchial stenosis
Pulmonary involvement Chest X-ray or CT-scan evidence
ANCA positivity By immunofluorescence or by
Enzyme-Linked Immuno-Sorbent Assay
(ELISA) PR3-ANCA or MPO-ANCA
or EGPA have been reported (25, 160), Non-specific findings
such as fever, fatigue, anorexia, and weight loss may precede
the systemic manifestations. Other symptoms may include
gastrointestinal, mucosal and skin lesions, ocular abnormalities,
arthralgia, nervous system involvement, and deep venous
thrombosis (163).
The most common clinical presentation of GPA involves
the upper respiratory tract (up to 92% of adult patients). This
feature might be shared with EGPA, but is rarely seen with MPA.
Involvement of the upper respiratory tract (rhinitis, sinusitis,
nasal crust, epistaxis, otitis media, sensorineural or conductive
hearing loss) precludes the diagnosis of MPA (164). Subglottic
TABLE 7 | Classification criteria of MPA according to the Annals of the Rheumatic
Diseases of the BMJ.
Criterion Score
Pauci-immune glomerulonephritis +3
Blood nasal discharge, ulcer, crusting, congestion
or blockage, septal defect/perforation
−3
pANCA or MPO-antibody positivity +6
Fibrosis or Interstitial Lung Disease on chest imaging +3
cANCA or PR3-antibody positivity −1
Eosinophil count ≥1 × 10 (9)/L −4
Total score ≥6 is needed (Sensitivity 87%, Specificity 96%).
tracheal stenosis is a severe complication and that occurs 5 times
more frequently in pediatric patients than in adults (163).
Lower respiratory tract involvement is a shared feature
in all AAV subtypes (cough, wheezing, hemoptysis, and
bronchial stenosis). Catastrophic pulmonary hemorrhage may
also occur in up to 42% patients in MPA (164). Eosinophilic
granulomatosis with polyangiitis predominantly affects the
airways, less frequently the skin, heart, gastrointestinal tract,
or nervous system. Renal involvement is the most important
concern. It is a severe manifestation in GPA and MPA, often
leading to ESRD and thus causing significant morbidity and
mortality. It commonly manifests as a pauci-immune necrotizing
GN, with a variety of clinical phenotypes, ranging from rare cases
of “slowly progressive” forms of GN, characterized by isolated
urinary abnormalities (microscopic hematuria, blood-red casts
and/or proteinuria), to a more frequent manifestation including
acute severe kidney injury often requiring renal replacement
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therapy in the context of a crescentic glomerulonephritis (a
rapidly progressive form of AAV GN) (162). Usually, AAV leads
to a normocomplementemic form of GN.
Renal involvement in AAV is common. In MPA, it is present
in 94–100% of patients at onset (164), whereas GPA renal
involvement has been noted in 50–100% of children at onset
(163). To date, no pediatric case report has described renal injury
in EGPA (25, 160).
Natural History and Prognosis
Prompt diagnosis is closely correlated with a favorable prognosis.
If organ-specific findings are only mild, a delay in diagnosis
may result in chronic, irreversible lesions. Renal disease is
the most relevant determinant of long-term prognosis and
morbidity in children: more frequent and severe in MPA than
GPA, mild and not progressive in EGPA (ESRD up to 40%
in MPA vs. 10% in GPA) (60). ANCA serology (MPO or
PR3) is a relevant prognostic factor as regards outcome and
relapse risk (18). However, serum C3 consumption and/or C3
and immunoglobulin glomerular focal deposition and sclerotic
lesions predict an adverse outcome (60, 81). Patients with MPA
and pulmonary-renal involvement and high MPO-ANCA titers
progress to ESRD within 1 to 5 years (81). If untreated, GPA has a
mortality rate of 100% in the first year, while it recurs in up to 60%
of treated patients (17). The mortality rate in treated children
is <5–10% (60). Kidney transplantation is recommended during
periods of clinical and serological remission, and the disease can
recur in the graft.
Pathogenesis
A multifactorial pathogenesis is involved in the development of
AAV: genetic and epigenetic factors interact with environmental
(infections, drugs and air pollutants), hormonal and
immunological alterations. Some HLA-DP alleles are associated
with a major risk for developing GPA. Mutations in the
SERPINA1 gene encoding for alpha1-antitrypsin, the principal
inhibitor of PR3, and in PR3 encoding gene (PRTN3) may
predispose to GPA. Conversely, MPA is associated with HLA-DQ
polymorphisms (160, 165).
High levels of MPO and PR3 are noted on the surface of
primed circulating neutrophils, where they are most exposed to
the action of autoantibodies (164). Regardless of the trigger, a
series of events occurs leading to B cell dysregulation which,
in association with an imbalance between helper and effector T
cells, leads to ANCA production and neutrophil activation with
consequent tissue damage and vessel inflammation. A role of
CAP has been demonstrated (60) in neutrophil activation and
renal damage (166).
Clinical Meaning of Serum ANCA
Serology, namely ANCA analysis, is needed to differentiate GPA
from MPA, with a high sensitivity (93%) and specificity (90%).
Granulomatosis with polyangiitis usually shows anti-PR3 ANCA
positivity in 60–80% of cases, with MPA anti-MPO ANCA in
80–90% and EGPA in 35–40% of cases, respectively (160, 162).
In limited disease forms, or in EGPA, ANCA screening is
often negative (160). Isolated renal vasculitis has been described
with 80% MPO-ANCA positivity, causing a rapidly progressive
GN (162).
The pathogenetic role of ANCA has been questioned. Murine
in vivo studies demonstrate that it is possible to induce GN by
transferring anti-MPO antibodies. Furthermore, the association
between PR3-AAV and both polymorphisms in HLA and a
mutation in PR3 encoding gene suggest a pathogenetic role.
Finally, the relationship between ANCA titer and disease activity
is not clear-cut, the evidence that some antibody-depletion
therapies, such as plasma-exchange and anti-CD20 monoclonal
antibody are efficacious in AAV support the pathogenetic
hypothesis. It is worth underlining that some patients without
AAV may have significant ANCA titers. The antibodies appear
directed against “non-pathogenetic” epitopes (166).
Renal Histopathology
The histological picture typically shows a pauci-immune, focal
necrotizing and crescentic GN (162, 165). Immunofluoresence
is typically negative (Figure 9). Recently, a histopathologic
classification has been validated for the pediatric forms,
which correlates with renal function at 2 years: focal lesions
demonstrated better outcome compared to crescentic/mixed
lesions and sclerosis (162). Tubularsclerotic lesions, C3 and
immunoglobulin focal deposition on IF are also markers of
adverse outcome (160).
Treatment
The EULAR-ERA EDTA recommendations and the
SHARE project indicate intravenous high dose steroids and
cyclophosphamide for 3–6 months as the first-line therapy in
children (Table 3). Rituximab is an alternative for children with
refractory or relapsing disease (60, 61). Mycophenolate mofetil
has been trial tested as an induction therapy with positive results
in children with more frequent relapses. Plasma exchange is an
optional treatment in rapid progressive renal failure or when
alveolar hemorrhage is present. In the maintenance phase, a
combination of low-dose steroids and azathioprine, rituximab or
MMF can be used for an undefined follow-up period (160, 167).
With adequate therapy, remission can be achieved in 70–100 %
of patients (168). TNF-alfa receptor blocker (etanercept), TNF
monoclonal antibody (infliximab), cytotoxic T lymphocyte-
associated antigen 4 (CTLA-4) IgG Fc fusion protein (abatacept),
human anti-CD52 monoclonal antibody (alemtuzumab),
antiIL-6 receptor human monoclonal antibody (tocilizumab),
and anti IL-5 human monoclonal antibody (mepolizumab)
have been tested in adults with promising results, but they are
recommended in children to date (169).
Our protocol involves an initial course of intravenous boluses
of methylprednisolone (15–30 mg/kg/dose maximum 1 gr
for three consecutive days), followed by oral prednisone (1
mg/kg/day) for 4 weeks, and then slow tapering. The steroids are
accompanied by cyclophosphamide (orally 2–3 mg/kg/day for 8–
12 weeks, with a maximum 150 mg/kg cumulative dosage, or
intravenously 500 mg/dose every 2 weeks repeated 6 times) or by
plasma exchange, depending on the severity of disease. We prefer
to utilize MMF rather than azathioprine in the maintenance
period, in association with progressively tapered oral steroids.
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FIGURE 9 | ANCA Associated Vasculitis Nephritis. (A) Diffuse crescentic, sclerotic and focal necrotizing GN. Diffuse interstitial flogistic infiltration. One glomerulus is
almost completely fibrotic. (B) pauci-immune IF pattern with evidence of fibrinogen deposition due to diffuse hyalinosis. C3 focal deposition. (C) EM, diffuse sclerosis.
RAPIDLY PROGRESSIVE
GLOMERULONEPHRITIS
This definition comprises the spectrum of abovementioned
clinical conditions and is characterized by a rapid onset
of progressive acute renal failure, in combination with a
nephritic syndrome. The pathognomonic histological picture
is crescents in more than 30% of the glomeruli, overlapping
the principal features of an active GN. Complement status
depends on the type of RPGN: elevated levels are found
in systemic vasculitis, otherwise levels are decreased in SLE
and other forms of IC-related GN (170). It is important to
consider that, generally speaking, RPGN has to be considered
as a sub-class of the abovementioned form of GN. For this
reason, the most appropriate classification of RPGN is based
on the presence, localization, and extent of deposits on IF.
Three main forms are recognized: 1. IC-mediated, 2. anti-
GBM mediated and 3. pauci-immune forms, often associated
with ANCA.
1. IC-RPGN is the most severe clinical and histological
form, particularly in children with PIGN, IgAN, IgAV and
lupus nephritis. Around 10–15% of PIGN present as a rapidly
progressive form. In the treatment of the rapidly progressive
forms of these IC-related RPGN, the use of cyclophosphamide
must be considered (see paragraph on the specific forms of GN).
2. Anti-GBM RPGN (Goodpasture syndrome) has an incidence
of approximately 0.5 to 1 per million per year in adults and is
even more rare in children (171). Reported pediatric cases are
very scarce (n = 31) and show a prevalence in girls (M/F sex
ratio, 1:4) and mean age at diagnoses of 9.2 ± 4.6 years (172).
Goodpasture syndrome (GS) typically has a bimodal distribution
with a pediatric peak between 10 and 20 years of age and a
second peak after 60 years of age. Clinical manifestations can
start following a triggering event (upper respiratory infection,
smoking, hydrocarbon exposure, or influenza). Symptoms can be
nonspecific (malaise, weight loss, fever, and arthralgia) or include
severe renal and pulmonary manifestations. Kidney disease may
occur independently from pulmonary disease and can range
from hematuria and proteinuria to rapidly progressive renal
failure. Pulmonary involvement, if present, may precede renal
symptoms by weeks to months. Hemoptysis associated with
respiratory failure is very common, due to the typical pulmonary
bleeding. In sub-clinical cases, anemia and iron deficiency can be
evident (173).
The current mortality rate is about 30% in children,
mainly due to severe pulmonary hemorrhage. Early treatment
improves survival rates. Prognosis for renal recovery is worse
in the presence of oliguria, presenting creatinine >5 mg/dl
or renal biopsy showing >50% crescent formation within
glomeruli at time of diagnosis or evidence of diffuse chronic
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FIGURE 10 | Rapidly Progressive Glomerulonephritis due to anti-GBM antibodies. (A) LM (PAS Stain); membranoproliferative, crescentic and sclerotic pattern
associated with interstitial infiltration of leukocytes (endo-extracapillary pattern). (B) IF: Linear deposits of IgG along the capillary wall. (C) EM: shows no deposits and
the presence of sclerosis.
damage (174). No residual pulmonary deficit or fibrosis
is noted once the patient has recovered from the acute
presentation. Though very rare, recurrence of the disease
can occur, Goodpasture syndrome is associated with anti-
GBM antibodies that localize in NC1 domain of the alpha3
chain domain of collagen IV, present in the GBM of kidneys
and pulmonary alveoli. Linear deposits of IgG along the
capillary wall are present on IF, while on LM, the glomeruli
show breaks of the GBM due to fibrinoid necrosis and the
consequent development of cellular crescents (Figure 10). In
the very early stages of the disease, crescents may not be
apparent, even in patients who present with severe, life-
threatening lung disease. Other features include: Bowman’s
capsule ruptures, periglomerular fibrosis, fibrocellular/fibrous
crescents, interstitial lymphoplasmacytic infiltrates, particularly
around crescentic glomeruli, interstitial fibrosis, and tubular
atrophy. A granulomatous or giant cell reaction may be present.
No deposits are seen on EM, as the deposits have the same density
as the GBM.
The initial treatment of choice is plasmapheresis to
remove circulating antibodies. Immunoadsorbtion is an
effective alternative therapy. Immunosuppressive therapy
could include corticosteroids and cyclophosphamide or
rituximab to reduce antibody production. Low dose prednisone,
azathioprine, or mycophenolate may be used for maintenance
immunosuppression once remission is established (175, 176). It
is important to monitor levels of Anti-GBM antibodies weekly,
until two negative results have been obtained, and then monthly
for up to 6 months.
3. Pauci-immune RPGN is characterized by a complete
absence of findings on IF. This group comprises a number of
inflammatory diseases involving small vessels, as described in
the paragraph about AAV. The co-presence of both ANCA and
anti-GBM antibodies is relatively rare and requires aggressive
and early treatment due to the extremely severe course. For
this reason, we strongly suggest monitoring for anti-GBM
antibody appearance in patients with AAV in order to start early,
appropriate treatment to improve prognosis.
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